Intellia Therapeutics Inc (NTLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Intellia Therapeutics Inc (NTLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH2342362D
  • |
  • Pages: 46
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Intellia Therapeutics Inc (Intellia Therapeutics) is a biotechnology company that develops proprietary curative therapeutics using CRISPR/Cas9 system. The company develops in vivo programs for treating liver diseases such as transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus and primary hyperoxaluria. It also develops ex vivo programs for chimeric antigen receptor T cells and hematopoietic stem cells. Intellia Therapeutics conducts genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The company partners with other pharmaceutical and bioscience companies to develop its products. Intellia Therapeutics is headquarterd in Cambridge, Massachusetts, the US.

Intellia Therapeutics Inc (NTLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Intellia Therapeutics Raises USD70 Million in Series B Financing 12

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 14

Partnerships 15

Intellia Therapeutics and San Raffaele University and Research Hospital Enter into Research Agreement 15

Licensing Agreements 16

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 16

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 18

Intellia Therapeutics Signs Licensing Agreement with Caribou Biosciences 20

Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 21

Equity Offering 22

Intellia Therapeutics Raises USD124.4 Million in IPO 22

Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 24

Intellia Therapeutics Inc-Key Competitors 26

Intellia Therapeutics Inc-Key Employees 27

Intellia Therapeutics Inc-Locations And Subsidiaries 28

Head Office 28

Recent Developments 29

Strategy And Business Planning 29

Jan 12, 2016: Intellia Therapeutics Launches New Division to Accelerate Ex Vivo Programs with CRISPR/CAS9 29

Financial Announcements 30

Aug 01, 2017: Intellia Therapeutics Announces Second Quarter 2017 Financial Results 30

May 02, 2017: Intellia Therapeutics Announces First Quarter 2017 Financial Results 32

Mar 14, 2017: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2016 Financial Results 34

Nov 01, 2016: Intellia Therapeutics Reports Financial Results for Third Quarter 2016 37

Aug 04, 2016: Intellia Therapeutics Reports Financial Results for Second Quarter 2016 38

Corporate Communications 39

Jul 24, 2017: Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee 39

Dec 13, 2016: Intellia Therapeutics Names Graeme Bell Chief Financial Officer 41

Apr 22, 2016: Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors 42

Legal and Regulatory 43

Apr 13, 2017: CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appeal of CRISPR/Cas9 U.S. Patent Board Decision 43

Product News 44

Mar 08, 2017: Intellia Therapeutics Demonstrates Pioneering CRISPR/Cas9 Genome Editing Efficiency Data Using Lipid Nanoparticle Delivery Technology 44

Other Significant Developments 45

Dec 01, 2016: Intellia Therapeutics Opens New Headquarters as Company Continues to Advance CRISPR/Cas9 Platform and Pipeline 45

Appendix 46

Methodology 46

About GlobalData 46

Contact Us 46

Disclaimer 46

List of Figures

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Intellia Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Intellia Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Intellia Therapeutics Raises USD70 Million in Series B Financing 12

Intellia Therapeutics Raises USD15 Million in Series A Venture Financing 14

Intellia Therapeutics and San Raffaele University and Research Hospital Enter into Research Agreement 15

CRISPR Therapeutics Enters into Licensing Agreement with Intellia Therapeutics, Caribou Biosciences, ERS Genomics, University of California and University of Vienna 16

Regeneron Pharma Enters into Licensing Agreement with Intellia Therapeutics 18

Intellia Therapeutics Signs Licensing Agreement with Caribou Biosciences 20

Novartis Enters into Research and Licensing Agreement with Intellia Therapeutics 21

Intellia Therapeutics Raises USD124.4 Million in IPO 22

Intellia Therapeutics Raises USD70 Million in Private Placement of Series B Preferred Stock 24

Intellia Therapeutics Inc, Key Competitors 26

Intellia Therapeutics Inc, Key Employees 27

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Intellia Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16120
Site License
USD 500 INR 32240
Corporate User License
USD 750 INR 48360

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com